Background: Escalating rates of prescription opioid use and abuse have occurred in the context of efforts to improve the treatment of nonmalignant pain.
C
hronic pain affects approximately 100 million adults in the United States 1 and pain is the most common reason why patients seek health care. 2, 3 The medical and lost productivity costs of chronic pain are enormous, estimated at $635 billion dollars annually. 1 Over the past 30 years, a growing awareness of the prevalence and disability associated with pain has prompted a variety of initiatives to improve its identification and management. [4] [5] [6] [7] These efforts have also coincided with a sharp increase in opioid use and abuse in the United States. [8] [9] [10] [11] By 2010, approximately 5.1 million individuals aged 12 years and older reported current nonmedical use of pain relievers, 12 which has contributed to consistent increases in the number of emergency department visits and deaths associated with illicit prescription opioid use. 13, 14 By 2008, the annual number of fatal drug poisonings surpassed those of motor vehicle deaths 15 and overdose deaths attributable to prescription drugs exceeded those of cocaine and heroin combined. 16 The epidemic of prescription drug abuse in the United States has renewed the challenge of appropriate identification and management of pain in ambulatory settings. Despite efforts to better identify and treat patients in pain, 5, 6, 17 campaigns to improve pain management may have unintended consequences. [18] [19] [20] [21] We examined the diagnosis and management of nonmalignant pain in ambulatory settings between 2000 and 2010 using a large, nationally representative federal survey of physicians. In addition to examining secular trends, we were especially interested in whether increases in opioid utilization have been accompanied by similar increases in the use of nonopioid analgesics.
METHODS

Data
We analyzed data from the 2000-2010 National Ambulatory Medical Care Survey (NAMCS), 22 a nationally representative, annual sample of outpatient office visits that provides data on patient and physicians. 23 The NAMCS requests physicians and office staff to complete a one-page form for a systematic random sample of office visits that occur during a one-week period. These data include information about the physician, patient, reason for visit, diagnoses, and prescribed and over-the-counter medications. Masked sampling design variables were included to adjust for nonparticipation and nonresponse and to allow for national projections.
Cohort Derivation
The NAMCS patient record includes up to three patient-reported symptoms and three physician-reported diagnoses for each visit. We used medical coding software, 24 manual keyword searches, and clinical judgment to identify visits with a primary patient self-reported symptom or physician-reported diagnosis related to pain or, in subset analyses, new musculoskeletal pain. In all analyses, we excluded individuals younger than 18 years of age (19% of all visits) and those with a diagnosis of cancer (6% of adult visits). A total of 7.8 million weighted visit records were analyzed.
Outcomes
We focused on pharmacologic treatments including opioids, nonopioids, and adjuvant therapies. We used the 2010 NAMCS survey documentation, which classifies drugs using the Multum drug ontology, 23 to group pharmacologic therapies into mutually exclusive subclasses (Supplementary Table 1 , Supplemental Digital Content 1, http://links.lww.com/MLR/A579). We excluded analgesic antitussives and expectorants. We used a similar approach to identify and group nonopioid pharmacologic therapies, such as nonsteroidal inflammatory therapies, acetaminophen and aspirin. In some analyses, we examined the prescribing of select adjunctive therapies used to manage pain, including anticonvulsants, tricyclic antidepressants, and in the case of musculoskeletal pain, muscle relaxants, injectable and topical treatments, and nonpharmacologic therapies such as acupuncture.
Analysis
We used descriptive statistics to compare the patient, provider, and practice characteristics of visits with a primary symptom or diagnosis of pain and their counterparts. Next, we examined the prevalence of pain during each year. We then focused on patients with a new symptom or diagnosis of musculoskeletal pain, examining the proportion of patients who received different therapies. To do so, we categorized each visit as one of the two (or, in the case of new musculoskeletal pain, three) types: (1) opioid visit, which we defined as any visit where an opioid was dispensed; (2) nonopioid pharmacologic visit, which we defined as any visit where a nonopioid analgesic was used without any opioid therapy; and, in the case of musculoskeletal pain, (3) nonmedicine visits, which we defined as any visit where complementary and alternative or physical therapy was used irrespective of any analgesic medicine.
To build our regression models, we defined our outcome as the receipt of an opioid rather than nonopioid analgesic for new musculoskeletal pain. First, we quantified the bivariate associations. We then conducted multivariate logistic regression, including variables that were basic demographic characteristics, of at least borderline statistical significance on bivariate analysis (P < 0.10) or in which we had a substantive a priori interest. To examine how the likelihood of opioid receipt varied across different groups of patients, providers, and visits, we used the coefficients from the multivariate models to derive the predicted probability of opioid receipt for the period 2000-2002 and the period 2006-2010, calculating these at the mean levels of other variables in the models. We accounted for the complex survey design of NAMCS using study design parameters and sample weights provided by the National Center for Health Statistics. All analyses were carried out using SAS version 9.2.
Sensitivity Analyses
We included several analyses to assess our results under different assumptions, including: (1) examining visits with symptoms of pain separately from diagnoses of pain and including visits with secondary or tertiary symptoms or diagnoses; (2) quantifying how our findings varied when including subjects in our denominator who received a nonpharmacologic therapy for musculoskeletal pain; (3) identifying predictors of opioid utilization among all pain visits rather than new musculoskeletal visits; (4) considering the potential interaction between year of observation and several patient characteristics, including age, race, and payment source; and (5) repeating analyses excluding over-the-counter medications because of potential underestimation of these drugs in the NAMCS survey. (Table 1) . Overall, patient, provider, and visit characteristics were generally similar between those associated with pain and those that were not.
Trends in Patient Symptoms and Provider Diagnoses of Pain
Absolute rates of reported pain as a primary symptom or diagnosis fluctuated <2% during the period examined and consistently represented approximately one-fifth of visits (Fig. 1) . Rates of pain including cases where it was reported as a secondary or tertiary symptom or diagnosis were somewhat greater (Appendix Table 1 ). Patient-reported pain as a primary symptom was consistently approximately 17%-19% of visits, whereas provider-reported pain increased nearly 50% from 2000 [5.7% of visits with pain as a primary diagnosis, 95% confidence intervals (CI), 4.96%-6.49%] to 2010 (8.5%, 95% CI, 7.53%-9.42%). Musculoskeletal pain represented about half of all nonmalignant pain visits from 2000 to 2010. Table 2 depict the prevalence and treatment of pain among patient visits from 2000 to 2010. In 2000, there were 130 million patient visits where pain was either a primary symptom or diagnosis and of these, opioids were prescribed in 11% (95% CI, 9.11%-13.53%), whereas approximately 60% (95% CI, 57.86%-64.33%) had no pharmacologic treatment. There were modest declines in the proportion of visits with no pharmacologic pain treatment from 2000 (61.10% of visits) to 2010 (53.35% of visits).
Pharmacologic Treatment of Pain
Over the period examined, two-fifths to one-half (40%-50%) of pain visits were associated with an analgesic use. Although rates of opioid use increased 73% from 11.3% of visits (2000) to 19 .6% of visits (2010), prescribing rates of nonopioid pharmacotherapies remained relatively constant (26%-29%). In 2010, the final year of observation, of 164 million pain visits, approximately one-half The concomitant use of opioids with nonopioids analgesics increased during the time period examined. Among all pain visits, opioid with NSAID prescribing increased 39%, from 3.7% of visits (2000) to 5.2% of visits (2010). There were also increases in use of acetaminophen (from 0.5% to 0.6% of visits) and adjunctive therapies (from 2.9% to 7.1% of visits) with opioids, although patients receiving these combinations of therapies still represented a small proportion of all pain visits.
Pharmacological Treatment of New Musculoskeletal Pain
From 2000 to 2010, ambulatory care visits where new musculoskeletal pain was either a primary symptom or diagnosis increased from 62 million visits to 87 million visits (Table 2 ). Approximately one-half of visits in a given year were treated with analgesics. During 2005-2010, the years 
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Patient, Provider, and Practice Characteristics Associated With Nonopioid Use
Few patient, practice, and physician characteristics were associated with the likelihood of receiving an opioid versus a nonopioid analgesic for a new primary symptom or diagnosis of musculoskeletal pain. For example, on bivariate analysis, rates of opioid receipt were similar among subjects of different ages and opioid receipt did not differ based on patients' sex, number of comorbid conditions, or whether the patient was new to the practice or physician. On multivariate analysis, the likelihood of opioid receipt was lower among older patients, Hispanics, those on fewer medicines, individuals with a private insurance, and those patients whose self-identified race was neither white nor Black, as compared with their counterparts (Table 3) . Over the period examined, increases in opioid use generally occurred nonselectively rather than being concentrated in particular subpopulations of visits.
Sensitivity Analyses
Sensitivity analyses supported our analytic approach and the robustness of our results. Although the prevalence of pain was greater when examining subjects with a postoperative visit or with any symptom rather than a primary symptom or diagnosis of pain, the substantive results and their interpretation were unchanged. Multivariate analyses including subjects in our denominator who received a nonpharmacologic therapy for musculoskeletal pain also yielded substantively similar results, as did models that examined all subjects with pain rather than those with new musculoskeletal pain. In most cases, the year of observation did not modify the independent association between these patient characteristics and the likelihood of opioid receipt, and interactions terms were excluded from the final model. Finally, in analyses that excluded over-the-counter medications from analysis because of their potential for systematic under capture and the differential impact of this over the period examined, our results showed even larger decreases in NSAIDs prescribing for all pain and new musculoskeletal pain.
DISCUSSION
Using nationally representative data on ambulatory practice in the United States, the overall prevalence of patient-reported pain has not changed during the past decade, although providers' diagnoses of pain as a primary complaint nearly doubled. Despite large increases in opioid use, there were not similar increases in the prescribing of alternative analgesics, such as NSAIDs, acetaminophen, and other therapies that may serve as alternatives to prescription opioids. These results are important given the epidemic rates of prescription opioid abuse that have occurred in the context of efforts to improve the identification and treatment of nonmalignant pain. Although escalating opioid utilization has been well described, 11, 13, 25 our analyses represent some of the most comprehensive to date examining trends in the ambulatory diagnosis and treatment of pain. Our findings have implications for patients, providers, and policy-makers and highlight the need for more evidence demonstrating the safety and effectiveness of opioid compared with other analgesics. Despite greater recognition of pain by providers and a remarkable increase in opioid prescribing, there was no commensurate increase in the prescribing of nonopioid therapies. This is particularly important because of the variety of alternative pharmacologic treatments available to treat nonmalignant pain, including selective and nonselective NSAIDs, acetaminophen, some anticonvulsants, tricyclic antidepressants, and in the case of musculoskeletal pain, muscle relaxants, topical analgesics and local injections. 1, 26 The removal of rofecoxib from the market in 2004 may have increased providers' awareness of adverse events related to NSAIDs and thus contributed to the decrease in NSAID use for the treatment of musculoskeletal pain. However, there is little evidence to support any greater safety or effectiveness of opioids over many of these alternative analgesics, particularly with respect to functional outcomes and longer term use. 27 Indeed, despite large escalations in clinical adoption, trials of opioids have generally been placebo-controlled, examined only short-term outcomes, and excluded patients with a history of substance abuse, depression, or other mental illness. 28 Although our results suggest the need for greater evidence about the comparative effectiveness of opioids and alternative treatments, 29 clinicians and policy-makers should use caution in extrapolating the findings of the current evidence with regard to opioids to clinical populations that differ considerably from the contexts in which they have been most studied.
In multivariate analyses, some patient or visits characteristics were associated with the likelihood of opioid receipt rather than nonopioid analgesic receipt for new musculoskeletal pain. Despite this, the overall clinical and policy magnitude of these differences was modest, findings which persisted when examining all pain rather than new musculoskeletal pain. In addition, we found that, in general, increases in opioid use have occurred nonselectively, rather than being focused within a particular group of patients, clinicians, or types of office visits. Although approximately one-fifth of office visits were associated with a primary symptom or diagnosis of pain, there were large increases in the total number of ambulatory pain visits, from 616 million in 2000 to 761 million in 2010. We also found an approximate 50% increase in provider diagnoses of pain, which may reflect the impact of campaigns such as the "Pain as the fifth vital sign" initiative 5, 6 and the World Health Organization pain ladder, 7 as well as an increasing number of therapies that have been marketed and promoted for its treatment. Nevertheless, there is still considerable discordance between patient and provider reports of pain, which may be due to a variety of factors, such as clinicians' tendency to diagnose underlying causes of pain rather than pain itself, 1 and is worthy of further investigation. This discordance and the large proportion of pain visits that did not result in analgesic use, are both worthy of further study, although neither should be used alone to infer insufficient pain treatment. For example, a prospective observational study of pain-related visits in the emergency department setting yielded results suggesting approximately one-half of patients may not desire pharmacological analgesia. 30 
Our Study has Several Important Limitations
First, although the NAMCS is uniquely well suited for the current analysis, its cross-sectional structure excludes some information of interest such as indication, pain chronicity, dosing, drug intolerance, treatment failures, and health outcomes, which limits our ability to judge the quality of pain management among these patients. Second, the NAMCS data may underestimate provider mentions of some over-thecounter therapies such as acetaminophen; however, prior analyses have demonstrated that the NAMCS captures a substantial proportion of these drug mentions. 31 Such under capture would primarily be of concern if it was systematically impacted by secular changes such as the market withdrawal of rofecoxib in 2004; however, our sensitivity analyses suggested substantive findings when excluding over-the-counter therapies from analysis. Finally, there are additional adjunctive pharmacological therapies (e.g., selective serotonin reuptake inhibitors, b-blockers, anticonvulsants, steroids) that may be prescribed off-label to treat pain; we conservatively excluded most of these therapies from our primary analyses because they are also used for a variety of nonanalgesic indications.
CONCLUSIONS
Many factors contribute to the complexity of the epidemic of prescription opioid abuse and diversion. One is that historically, pain has been undertreated in some settings. Despite this, our data suggest that the rapidly rising rates of opioid use have not been accompanied by increases in the proportion of ambulatory pain patients receiving pharmacologic treatment, nor have large increases in the ambulatory prescribing of opioids been accompanied by similar increases in the prescribing of nonopioid analgesics. Policy-makers, professional organizations, and providers should re-evaluate prior efforts to improve the identification, treatment, and management of nonmalignant pain and promote approaches that adequately reflect the importance of nonopioid and nonpharmacologic treatments. 
